Psoriasis Market Report 2026

The psoriasis market size has grown strongly in recent years. It will grow from $28.93 billion in 2025 to $31.41 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of autoimmune skin disorders, widespread corticosteroid usage, improved dermatology diagnosis rates, expansion of hospital dermatology units, growing awareness of chronic skin diseases.

The psoriasis market size is expected to see strong growth in the next few years. It will grow to $44.79 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growth in biologic drug approvals, rising patient awareness, increasing diagnosis of severe psoriasis, expansion of specialty clinics, higher healthcare spending on dermatology. Major trends in the forecast period include rising adoption of biologic therapies for psoriasis, increasing long-term disease management approaches, growing demand for injectable psoriasis treatments, expansion of hospital and specialty dermatology care, increased focus on moderate-to-severe psoriasis.

The increasing prevalence of psoriasis patients is anticipated to drive the growth of the psoriasis market in the coming years. Psoriasis is a chronic autoimmune skin condition characterized by accelerated skin cell turnover, resulting in inflammation, scaling, and discomfort, often necessitating ongoing medical management and monitoring. The rise in psoriasis cases is attributed to an overactive immune system that mistakenly attacks healthy skin cells, frequently triggered or worsened by environmental factors such as infections, stress, or skin injury. The growing number of psoriasis patients fuels the psoriasis market by increasing demand for biologics, topical therapies, immunomodulators, and phototherapy treatments aimed at reducing flare-ups, alleviating symptoms, and improving patient quality of life. For example, in 2025, according to the Global Psoriasis Atlas, a UK-based organization specializing in psoriasis research, an estimated 43 million individuals are diagnosed with psoriasis by physicians and dermatologists, while approximately 102 million people report having the condition based on self-assessments. Consequently, the rising prevalence of psoriasis patients is contributing to the expansion of the psoriasis market.

Major companies in the psoriasis market prioritize product innovation, such as autoinjector delivery systems for biosimilars, to enhance patient adherence, convenience, and outcomes while upholding the efficacy and safety of reference biologics; these enable self-administration, cut injection discomfort, and drive broader adoption in Europe and elsewhere - for instance, in May 2025, Switzerland's Sandoz launched Pyzchiva autoinjector, Europe's first commercial autoinjector for ustekinumab biosimilars, offering simple, precise, patient-friendly dosing to boost compliance in chronic psoriasis care and exemplifying the trend toward accessible, user-centric biologic delivery.

In October 2024, Organon, a U.S.-based healthcare company, acquired Dermavant Sciences, Inc., for an undisclosed amount to strengthen its dermatologic therapy portfolio by incorporating Dermavant's innovative treatments like VTAMA for psoriasis and other chronic skin conditions, thereby expanding its dermatology market presence; Dermavant, a U.S. pharmaceutical firm, specializes in pioneering dermatologic therapies with a solid track record in clinical development for psoriasis and related skin disorders.

Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy's Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy.

North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the psoriasis market by increasing the cost of imported biologics, injectable drugs, and specialty formulations used in chronic inflammatory disease management. These impacts are most evident in biologic and injectable segments, where manufacturing complexity and cold chain requirements are high. Regions such as North America and Europe have experienced higher input costs due to reliance on global specialty drug supply chains. Rising tariff related expenses have influenced pricing strategies, reimbursement negotiations, and procurement planning for psoriasis therapies. At the same time, tariffs have encouraged regional manufacturing, expanded domestic biologics capacity, and strengthened long term supply chain resilience.

The psoriasis market research report is one of a series of new reports that provides psoriasis market statistics, including psoriasis industry global market size, regional shares, competitors with a psoriasis market share, detailed psoriasis market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis industry. This psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Psoriasis is a skin condition that commonly impacts the knees, elbows, trunk, and scalp, leading to a rash with itchy, scaly patches. The main contributing factor may be a problem with the immune system, where infection-fighting cells mistakenly attack healthy skin cells.

The primary categories of drugs used in psoriasis include interleukin inhibitors, corticosteroids, anti-inflammatory agents, and tumor necrosis factor inhibitors. Corticosteroids are a class of steroid hormones produced by the adrenal cortex of vertebrates and also encompass their synthetic counterparts. The various types of drugs consist of small molecules and biologics and address multiple disease indications, such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. The available routes of administration include oral, topical, and injectable forms, with distribution channels spanning hospitals, retail pharmacies, and e-commerce platforms.

The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.